Two visions for value – Why GCEA and HEMA clash on drug pricing

That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin (FTI Consulting and Mann School of Pharmacy, University of Southern California) explores a widening divide over how health systems define value, and what that means…

Read More

Health Centers Face Risks as Government Funding Lapses

About 1,500 federally funded health centers that serve millions of low-income people face significant financial challenges, their leaders say, as the government shutdown compounds other cuts to their revenue. Some of these community health centers may have to cut medical and administrative staff or reduce services. Some could eventually close. The result, their advocates warn,…

Read More

Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease

Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup. The post Two Is Better Than One: Startup Dualitas Lands $65M to…

Read More